J&J’s Rybrevant Combination Therapy Outperforms AstraZeneca’s Tagrisso in Lung Cancer Survival Trial

Superior Survival Rates:
Johnson & Johnson's Rybrevant combination therapy demonstrated better overall survival rates compared to AstraZeneca's Tagrisso in a head-to-head study for non-small cell lung cancer (NSCLC) patients14.

Three-Year Data:
At three years, 61% of patients on the Rybrevant combination therapy achieved overall survival, compared to 53% of those treated with Tagrisso1.

Central Nervous System Disease Control:
The combination of Rybrevant and Lazertinib provided enhanced control of central nervous system disease compared to Tagrisso after three years, with a significantly higher intracranial progression-free rate (38% vs. 18%)1.

Treatment Outcomes:
45% of patients undergoing the combined treatment had not begun any subsequent therapy after three years, compared to 32% among Tagrisso patients, indicating a higher progression-free survival (PFS) in the group receiving the combination therapy1.

Approval and Future Prospects:
The Rybrevant combination therapy received approval from the US Food and Drug Administration as a first-line treatment option for NSCLC patients with specific EGFR mutations, and is expected to extend patients' median overall survival by at least a year more than Tagrisso14.

Sources:

1. https://finance.yahoo.com/news/j-j-rybrevant-combo-nsclc-103245398.html

4. https://www.bloomberg.com/news/articles/2025-01-07/j-j-says-lung-cancer-combo-improves-survival-more-than-astra-s-tagrisso